Active Biotech Year-end report January - December 2020
Fourth quarter in brief
Tasquinimod
The clinical study in multiple myeloma was presented at an oral poster session at the virtual American Society of Hematology (ASH) 2020 meeting in December
Patent granted in China in October regarding treatment of multiple myeloma
Patent granted in Europe in November regarding use of tasquinimod in combination with immunotherapy
Laquinimod
Naptumomab
Corporate
A Capital Markets Day was held on November 24
The clinical strategy and projected development milestones presented to the market in November
Significant events during the January-December period
Active Biotech announced a new strategic direction for the company in February
At least 36 people may have developed a rare blood disorder after covid vaccination: report foxnews.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from foxnews.com Daily Mail and Mail on Sunday newspapers.
At least 36 people may have developed a rare blood disorder, known as immune thrombocytopenia (ITP), after taking either Pfizer and BioNTech or Moderna's COVID-19 vaccines, according to a report.
717.5
-3.8%
(1) Further information on certain of Takeda’s Non-IFRS measures is posted on Takeda’s investor relations website at https://www.takeda.com/investors/reports/quarterly-announcements/ (2) Underlying growth compares two periods (quarters or years) of financial results under a common basis and is used by management to assess the business. These financial results are calculated on a constant currency basis and excluding the impact of divestitures and other amounts that are unusual, non-recurring items or unrelated to our ongoing operations. (3) Core Operating Profit represents net profit adjusted to exclude income tax expenses, the share of profit or loss of investments accounted for using the equity method, finance expenses and income, other operating expenses and income, amortization and impairment losses on acquired intangible assets and other items unrelated to Takeda’s core operations, such as purchase accounting effects and transaction related costs.
Regeneron Reports Fourth Quarter and Full Year 2020 Financial and Operating Results
News provided by
Share this article
Fourth quarter 2020 revenues increased 30% to $2.42 billion versus fourth quarter 2019
(4)
Fourth quarter 2020 EYLEA
® U.S. net sales increased 10% to $1.34 billion versus fourth quarter 2019 and full year 2020 EYLEA U.S. net sales increased 7% versus 2019
Fourth quarter 2020 Dupixent
(2)
, which are recorded by Sanofi, increased 56% to $1.17 billion versus fourth quarter 2019 and full year 2020 Dupixent global net sales increased 75% versus 2019
Fourth quarter 2020 GAAP diluted EPS was $10.24 and non-GAAP diluted EPS
(1)
™ antibody cocktail for COVID-19 received FDA Emergency Use Authorization; new agreement signed with U.S. government to purchase up to 1.25 million additional doses